| scholarly article | Q13442814 |
| P2093 | author name string | Radojka M Savic | |
| Jack Cook | |||
| Melanie R Nicol | |||
| David Wesche | |||
| Matthew L Rizk | |||
| Abhay Joshi | |||
| Jenny H Zheng | |||
| Philip E Sabato | |||
| P2860 | cites work | In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication | Q98205148 |
| Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases | Q106995834 | ||
| The pharmacokinetics of three multiple dose regimens of chloroquine: implications for malaria chemoprophylaxis | Q24538627 | ||
| Chloroquine is a potent inhibitor of SARS coronavirus infection and spread | Q24815979 | ||
| Hydroxychloroquine-related retinal toxicity | Q26782822 | ||
| Hydroxychloroquine in lupus pregnancy | Q33373145 | ||
| Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus | Q33422958 | ||
| Pharmacokinetics of chloroquine and monodesethylchloroquine in pregnancy | Q33676120 | ||
| New concepts in antimalarial use and mode of action in dermatology | Q34007922 | ||
| Transfer of drugs and other chemicals into human milk | Q34089033 | ||
| Assessment of azithromycin in combination with other antimalarial drugs against Plasmodium falciparum in vitro | Q34111879 | ||
| Disposition of the enantiomers of hydroxychloroquine in patients with rheumatoid arthritis following multiple doses of the racemate | Q34345489 | ||
| Absorption and in vivo dissolution of hydroxycholoroquine in fed subjects assessed using deconvolution techniques. | Q34345622 | ||
| Hydroxychloroquine: A Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation | Q50036781 | ||
| Stigmatization experience, coping and sense of coherence in vitiligo patients. | Q50906382 | ||
| Bioavailability of hydroxychloroquine tablets in healthy volunteers | Q34397314 | ||
| Excretion of chloroquine and desethylchloroquine in human milk | Q34416343 | ||
| A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers | Q34417966 | ||
| Pharmacokinetics of chloroquine in Thais: plasma and red-cell concentrations following an intravenous infusion to healthy subjects and patients with Plasmodium vivax malaria | Q34421133 | ||
| The effect of chloroquine on paracetamol disposition and kinetics | Q34447146 | ||
| Protein binding of chloroquine enantiomers and desethylchloroquine | Q34447948 | ||
| Disposition of chloroquine in man after single intravenous and oral doses | Q34512426 | ||
| Lack of effect of chloroquine on the debrisoquine (CYP2D6 and S-mephenytoin (CYP2C19) hydroxylation phenotypes | Q36093513 | ||
| Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen | Q36536401 | ||
| Population pharmacokinetics of a three-day chloroquine treatment in patients with Plasmodium vivax infection on the Thai-Myanmar border | Q36634918 | ||
| Transfer of chloroquine and desethylchloroquine across the placenta and into milk in Melanesian mothers | Q36729138 | ||
| Pharmacokinetics and Bioequivalence Study of Hydroxychloroquine Sulfate Tablets in Chinese Healthy Volunteers by LC-MS/MS. | Q36942997 | ||
| Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax | Q37144813 | ||
| Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects | Q37353434 | ||
| Feasibility, double-blind, randomised, placebo-controlled, multi-centre trial of hand-held NB-UVB phototherapy for the treatment of vitiligo at home (HI-Light trial: Home Intervention of Light therapy). | Q37582110 | ||
| Correlation of Vitamin D Levels with Pigmentation in Vitiligo Patients Treated with NBUVB Therapy | Q37733112 | ||
| Hydroxychloroquine: from malaria to autoimmunity | Q37827403 | ||
| Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases | Q38360827 | ||
| Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases | Q38561490 | ||
| Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine | Q39239760 | ||
| Pharmacokinetic interactions between primaquine and chloroquine | Q39370895 | ||
| Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). | Q39907371 | ||
| Population Pharmacokinetics of Hydroxychloroquine in Japanese Patients With Cutaneous or Systemic Lupus Erythematosus | Q40297767 | ||
| Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements | Q41192707 | ||
| Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications | Q41292997 | ||
| Enantioselective disposition of hydroxychloroquine after a single oral dose of the racemate to healthy subjects | Q41898692 | ||
| Placental and milk transfer of chloroquine in humans. | Q41912464 | ||
| Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria | Q41912987 | ||
| Chloroquine elimination in humans: effect of low-dose cimetidine | Q41913215 | ||
| Chloroquine in human milk | Q41913503 | ||
| Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis | Q41914929 | ||
| Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: A study of one hundred thirty‐three cases compared with a control group | Q41915008 | ||
| In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. | Q41915866 | ||
| Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis | Q41917273 | ||
| Hydroxychloroquine in human breast milk | Q41917613 | ||
| Evidence of transplacental passage of hydroxychloroquine in humans | Q41917690 | ||
| Pharmacokinetics of oral contraceptive steroids following the administration of the antimalarial drugs primaquine and chloroquine | Q41918657 | ||
| Pharmacokinetic aspects of chloroquine-induced pruritus: influence of dose and evidence for varied extent of metabolism of the drug | Q41919910 | ||
| The single dose kinetics of chloroquine and its major metabolite desethylchloroquine in healthy subjects | Q41919922 | ||
| Characterization of chloroquine plasma protein binding in man. | Q41921668 | ||
| Steady state disposition of chloroquine in patients with rheumatoid disease | Q41921988 | ||
| Hydroxychloroquine relative bioavailability: within subject reproducibility | Q41931238 | ||
| Case records of the Massachusetts General Hospital. Case 11-2011. A 47-year-old man with systemic lupus erythematosus and heart failure | Q41933034 | ||
| Significant reduction in chloroquine bioavailability following coadministration with the Sudanese beverages Aradaib, Karkadi and Lemon | Q41935405 | ||
| Bioavailability of hydroxychloroquine tablets in patients with rheumatoid arthritis | Q41935681 | ||
| Stereoselective pharmacokinetic properties of chloroquine and de-ethyl-chloroquine in humans. | Q41938174 | ||
| Plasma protein binding of the enantiomers of hydroxychloroquine and metabolites | Q41938734 | ||
| Steady-State Pharmacokinetics of Hydroxychloroquine in Rheumatoid Arthritis Patients | Q41941207 | ||
| Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases | Q41943895 | ||
| Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia | Q41945547 | ||
| Pharmacokinetics of chloroquine and some of its metabolites in healthy volunteers: a single dose study | Q41945879 | ||
| Chloroquine disposition in hypersensitive and non-hypersensitive subjects and its significance in chloroquine-induced pruritus | Q41946459 | ||
| Excretion of hydroxychloroquine in human milk | Q42532068 | ||
| Guidelines for management of atopic dermatitis | Q43270249 | ||
| Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro | Q84360011 | ||
| Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies | Q86824600 | ||
| Hydroxychloroquine and azithromycin as a treatment of COVID‐19: results of an open‐label non‐randomized clinical trial | Q87908797 | ||
| 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases | Q89851550 | ||
| In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | Q90160332 | ||
| Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State | Q90455461 | ||
| Treating COVID-19 with Chloroquine | Q90820646 | ||
| Diagnostic pitfalls and laboratory test interference after hydroxychloroquine intoxication: A case report | Q91047470 | ||
| SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells | Q91561671 | ||
| Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients | Q91627965 | ||
| Pharmacokinetics of Hydroxychloroquine in Pregnancies with Rheumatic Diseases | Q91747420 | ||
| Optimizing hydroxychloroquine dosing for patients with COVID-19: An integrative modeling approach for effective drug repurposing | Q91887557 | ||
| Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study | Q91916510 | ||
| Better prediction of the local concentration-effect relationship: the role of physiologically based pharmacokinetics and quantitative systems pharmacology and toxicology in the evolution of model-informed drug discovery and development | Q92316892 | ||
| Breast milk concentration of hydroxychloroquine in Chinese lactating women with connective tissue diseases | Q92378483 | ||
| Bi-directional differentiation of single bronchioalveolar stem cells during lung repair | Q92619966 | ||
| A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors | Q92971672 | ||
| Toxicokinetics of hydroxychloroquine following a massive overdose | Q93061683 | ||
| Assessment of Multi-Ion Channel Block in a Phase I Randomized Study Design: Results of the CiPA Phase I ECG Biomarker Validation Study | Q93186581 | ||
| Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial | Q93207522 | ||
| Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 | Q93254125 | ||
| Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19) | Q94503691 | ||
| [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19] | Q94549213 | ||
| Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State | Q94553295 | ||
| Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 | Q94606482 | ||
| Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial | Q94685789 | ||
| Connecting hydroxychloroquine in vitro antiviral activity to in vivo concentration for prediction of antiviral effect: a critical step in treating COVID-19 patients | Q95270917 | ||
| The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin | Q95628336 | ||
| A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 | Q96122302 | ||
| P921 | main subject | chloroquine | Q422438 |
| COVID-19 | Q84263196 | ||
| P577 | publication date | 2020-07-20 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection |
Search more.